Indian med-tech innovator Remidio is setting its sights on the United States and European markets after receiving a strategic investment boost from Rajat Khare’s deep-tech venture capital firm, Boundary Holding. The move marks a significant milestone in Remidio’s journey to transform global eye care through accessible, AI-powered diagnostic solutions.
Revolutionizing Eye Care Through Technology
With an aging global population and rising cases of preventable blindness, the demand for accessible and early eye-care diagnostics has never been greater. Studies over the past three decades have consistently shown that a significant proportion of vision impairment cases could be avoided through timely detection and treatment.
Remidio has built its foundation on solving exactly this problem.
Founded in India by Anand Sivaraman, the company develops AI-enabled, telemedicine-integrated ophthalmic devices designed to simplify comprehensive eye screening. By blending advanced technology with user-centric design, Remidio has made high-quality eye diagnostics portable, affordable, and usable even in non-specialist environments.
Their proprietary devices focus on detecting and managing conditions such as:
- Cataract
- Retinal diseases
- Glaucoma
- Refractive errors
These handheld tools allow healthcare workers, vision technicians, and even minimally trained volunteers to conduct screenings efficiently. From rural health centers to urban outreach programs and even supermarket-based screening initiatives, Remidio’s solutions are decentralizing eye testing like never before.
Investment That Fuels Global Ambition
The expansion into the US and Europe has been accelerated by investment from Boundary Holding, a Luxembourg-based deep-tech investment firm founded by Rajat Khare. The firm focuses on technologies driving the Fourth Industrial Revolution — particularly artificial intelligence, deep tech, and breakthrough innovations with strong societal impact.
After meeting Anand Sivaraman in India, Khare resonated strongly with his mission to democratize eye care. Recognizing both the technological robustness of Remidio’s platform and the founder’s long-term vision, Boundary Holding decided to back the company’s global growth ambitions.
This funding will enable Remidio to:
- Strengthen its R&D pipeline for existing and upcoming products
- Expand its sales and marketing footprint internationally
- Explore strategic acquisitions and partnerships
- Enter new application areas in ophthalmology and preventive healthcare
Why the US and Europe?
The US and European healthcare markets present significant opportunities for AI-driven diagnostic tools. Both regions face growing challenges linked to aging populations and rising healthcare costs. Preventive and early-detection technologies are increasingly becoming central to public health strategies.
Remidio’s portable, AI-integrated devices align well with this demand. By offering decentralized screening capabilities, the company can help reduce the burden on tertiary hospitals and specialist clinics while improving early diagnosis rates.
Moreover, telemedicine adoption has accelerated globally, making AI-powered ophthalmic devices more relevant than ever. Remidio’s ecosystem integrates seamlessly into modern healthcare frameworks, enabling remote diagnosis, digital record-keeping, and scalable screening models.
A Vision Beyond Borders
Vision impairment continues to affect millions every year — and what makes it more concerning is that many cases are preventable. Early detection plays a critical role in avoiding irreversible blindness, especially in conditions like glaucoma and diabetic retinopathy.
By leveraging artificial intelligence, compact engineering, and intuitive design, Remidio has already disrupted India’s eye-care delivery model. Now, with the backing of Boundary Holding, the company is positioned to replicate and scale this impact globally.
The investment is not just financial — it reflects a shared belief in technology as a force multiplier for public health.
As Remidio expands into the US and European markets, it aims to bring affordable, accessible, and high-quality eye diagnostics closer to communities worldwide. If successful, the partnership between Anand Sivaraman’s innovation-driven approach and Rajat Khare’s deep-tech investment philosophy could significantly reshape preventive ophthalmic care on a global scale.
In a world where millions still lose sight due to preventable causes, this expansion represents more than market growth — it represents a step toward making early eye-care access universal.
Source of url- https://businesscloud.co.uk/news/remidio-sets-its-sight-on-the-us-and-european-markets-after-investment-push-from-boundary-holding/

